Account
Cart

No products in the cart.

Awaiting product image

(Breo Ellipta™)RELVAR ELLIPTA™ 184/22

137.00 $

1 in stock

You need to add your prescription
SKU: 53565 Category:

Description

AsthmaRelvar Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: • patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short acting beta-2-agonists.• patients already adequately controlled on both inhaled corticosteroid and long-acting beta-2-agonist.

Additional information

Active Pharmacologic ingridient

vilanterol as trifenatate 22 mcg , fluticasone furoate 184 mcg
License holder

GLAXO SMITH KLINE (ISRAEL) LTD
Needs cooling?

No
need prescription?

yes
Administration

INHALATION
Dosage Form

POWDER FOR INHALATION
Drug includes

30 Dose inhaler
Patient Insert

https://mohpublic.z6.web.core.windows.net/IsraelDrugs/Rishum01_11_553065023.pdf
Storage Information

Store at room temprature. After opening the aluminium case, the inhaler can be used for up to 6 weeks.

Reviews

There are no reviews yet.

Be the first to review “(Breo Ellipta™)RELVAR ELLIPTA™ 184/22”

Your email address will not be published. Required fields are marked *

Related products

ANORO ELLIPTA®
0
from
139.00 $
INCRUSE ELLIPTA®
0
from
75.00 $
VENTOLIN® INHALER CFC FREE
0
from
18.00 $
Qvar® Aerosol Autohaler 100
0
from
63.00 $
To top
By using this service, I authorize Athenascripts.com or its agents to receive my prescription, supply medications from a pharmacy, and send them to me. I agree to waive my right to a pharmacist consultation (except for medications requiring pharmacological guidance) and understand that I can consult a pharmacist via email or phone.

Additionally, I consent to receive marketing messages from Athenascripts.com at the phone number provided. I understand I will receive notification messages, data rates may apply, and I can reply STOP to opt out.